{"ticker": {"uuid": "fb694c05-9d9d-4bb4-a412-86d9b0bc952d", "symbol": "ANIP", "name": "ANI Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter", "summary": "ANI Pharmaceuticals (ANIP) announced its intent to appeal rulings in the CG Oncology matter to the Delaware Supreme Court after a trial court denied its motions for a new trial and judgment. The company aims to recover the value of assets sold to CG Oncology in 2010, specifically", "url": "https://sg.finance.yahoo.com/news/ani-pharmaceuticals-announces-intent-appeal-203400188.html", "source_name": "Market source", "published_at": "2026-07-17T02:10:03", "published_display": "17 Jul 2026 02:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals plans appeal after trial court ruling By Investing.com", "summary": "ANI Pharmaceuticals announced its intent to appeal a Delaware trial court's denial of its post-trial motions in a dispute with CG Oncology. The company is seeking to recover the value of assets sold in 2010 and a 5% running royalty on future sales of cretostimogene grenadenorepve", "url": "https://ca.investing.com/news/stock-market-news/ani-pharmaceuticals-plans-appeal-after-trial-court-ruling-93CH-4738454", "source_name": "Investing.com Canada", "published_at": "2026-07-17T02:05:03", "published_display": "17 Jul 2026 02:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals Plans to Appeal Trial Court Rulings in CG Oncology Case", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ani-pharmaceuticals-plans-appeal-trial-211922359.html", "source_name": "MT Newswires", "published_at": "2026-07-16T21:19:22+00:00", "published_display": "16 Jul 2026 21:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPWDBfMjVQZWJ4bFFwbjUycnpmYUFsRm1hb1BvYi0xaXNTZ0MtYzYyUGVKQ21Mb2dselNjdnM1Q3NXSXR5VUdsWm91OUZLNnVnQkpsUFF0ZlNwWGVGc0FVSEVhSzAyWnRmVGYtX1hUUW9CZGVOaENBcVhhcERRN1hSZQ?oc=5", "source_name": "AOL.com", "published_at": "2026-07-16T19:39:25+00:00", "published_display": "16 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Frontier tech research, news & data", "summary": "This article analyzes the growth of ANI Pharmaceuticals Inc. (ANIP), focusing on its revenue, net income, and EPS growth rates year-over-year. It provides a detailed breakdown of these financial metrics on both an annual and quarterly (trailing-twelve-month) basis, highlighting s", "url": "https://mlq.ai/companies/ani-pharmaceuticals-inc/growth/", "source_name": "MLQ.ai", "published_at": "2026-07-15T04:45:33", "published_display": "15 Jul 2026 04:45", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Meredith Cook Sells 500 Shares of ANI Pharmaceuticals Inc (ANIP)", "summary": "Meredith Cook, Senior Vice President at ANI Pharmaceuticals Inc (ANIP), sold 500 shares of the company on July 13, 2026. This transaction continues a trend of insider selling over the past year, with no insider buys recorded against 52 insider sells. The stock is currently priced", "url": "https://www.gurufocus.com/news/8958706/insider-sell-meredith-cook-sells-500-shares-of-ani-pharmaceuticals-inc-anip", "source_name": "GuruFocus", "published_at": "2026-07-14T22:41:05", "published_display": "14 Jul 2026 22:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) counsel sells 500 shares under 10b5-1 plan", "summary": "ANI Pharmaceuticals' Senior Vice President, General Counsel, and Secretary, Meredith Cook, sold 500 shares of common stock at $81.84 per share on July 13, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established in September 2025. Following the sale, Cook", "url": "https://www.stocktitan.net/sec-filings/ANIP/form-4-ani-pharmaceuticals-inc-insider-trading-activity-df1390ac52a4.html", "source_name": "Stock Titan", "published_at": "2026-07-14T19:41:05", "published_display": "14 Jul 2026 19:41", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis", "summary": "ANI Pharmaceuticals announced positive six-month topline data from its Phase 4 SYNCHRONICITY clinical trial evaluating Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis (NIU-PS). The trial met both co-primary endpoints, showing statistica", "url": "https://www.sahmcapital.com/news/content/ani-pharmaceuticals-announces-positive-six-month-topline-data-from-the-phase-4-open-label-single-arm-synchronicity-trial-evaluating-fluocinolone-acetonide-intravitreal-implant-in-patients-with-chronic-non-infectious-uveitis-2026-07-13", "source_name": "Sahm", "published_at": "2026-07-14T02:10:03", "published_display": "14 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant", "summary": "ANI Pharmaceuticals Inc (NASDAQ:ANIP) announced positive topline results from its Phase 4 SYNCHRONICITY trial for a fluocinolone acetonide intravitreal implant used to treat chronic non-infectious uveitis. The study successfully met both primary endpoints, showing improved vision", "url": "https://www.proactiveinvestors.com.au/companies/news/1095359/ani-pharmaceuticals-reports-phase-4-data-for-uveitis-eye-implant-1095359.html", "source_name": "Proactive financial news", "published_at": "2026-07-13T13:41:19", "published_display": "13 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eye implant trial from ANI Pharmaceuticals improves vision and retinal thickness at 6 months", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNRVAwTllqdlQ1ZGQxX1lfYnZFZUNlOXpMLW92eUtGSFRhODNPNV9pNWZLY2dSX1R4UjY2bFJZZlVvZEVoTjRCbm5BLUV2U08wMTYwdmJKbnY3MG1FYW1KMEU0UktYaWo4dTJhR3V5b3RHUE85VWhjTlJXX3IweWJmSC16UFVpZVVlQ1FSd09CejdwdldBM3JZZVJBTF9FejZtUG5qWEdyVGFFWm4xWWJqd0I2aC15VzRxbkIzVjJn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:50:00+00:00", "published_display": "13 Jul 2026 10:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals reports positive phase 4 trial results", "summary": "ANI Pharmaceuticals (NASDAQ: ANIP) announced positive results from its Phase 4 SYNCHRONICITY clinical trial for fluocinolone acetonide intravitreal implant, which met both co-primary endpoints for treating chronic non-infectious uveitis. The trial demonstrated significant improve", "url": "https://www.investing.com/news/company-news/ani-pharmaceuticals-reports-positive-phase-4-trial-results-93CH-4787990", "source_name": "Investing.com", "published_at": "2026-07-13T11:10:25", "published_display": "13 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals reports positive uveitis trial results", "summary": "ANI Pharmaceuticals (NASDAQ:ANIP) announced positive six-month results from its Phase 4 SYNCHRONICITY trial for a fluocinolone acetonide intravitreal implant used to treat chronic non-infectious uveitis. The trial met both primary endpoints, demonstrating significant improvements", "url": "https://grafa.com/en/news/united-states/ani-pharmaceuticals-synchronicity-uveitis-trial-results", "source_name": "grafa.com", "published_at": "2026-07-13T11:06:00", "published_display": "13 Jul 2026 11:06", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of ANI Pharmaceuticals, Inc. \u2013 BX:BSFA", "summary": "This article focuses on the enterprise value to EBIT forward ratio for ANI Pharmaceuticals, Inc. (BX:BSFA). It appears to be a financial data point from TradingView, indicating a specific financial metric for the company. The content itself seems to be a page snippet from a finan", "url": "https://www.tradingview.com/symbols/BX-BSFA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T01:10:25", "published_display": "13 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) Recalls HydrOXYzine Solution, Is The Pullback A Valuation Opportunity?", "summary": "ANI Pharmaceuticals has initiated a Class III recall of its hydrOXYzine Hydrochloride Oral Solution due to a foreign substance, causing a short-term dip in its stock price. Despite this, the company has shown strong long-term shareholder returns, and a widely followed valuation n", "url": "https://www.sahmcapital.com/news/content/ani-pharmaceuticals-anip-recalls-hydroxyzine-solution-is-the-pullback-a-valuation-opportunity-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T13:40:04", "published_display": "11 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge", "summary": "Stephen Carey, CFO of ANI Pharmaceuticals, sold 2,850 shares of common stock worth $239,742 as part of a pre-scheduled Rule 10b5-1 plan. This sale represented a modest 1.6% reduction of his direct holdings and is not considered a signal of a negative outlook on the company. The c", "url": "https://finance.yahoo.com/markets/stocks/articles/ani-pharmaceuticals-cfo-sells-240-215646356.html", "source_name": "Market source", "published_at": "2026-07-09T22:17:05", "published_display": "09 Jul 2026 22:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of ANI Pharmaceuticals, Inc. \u2013 NASDAQ:ANIP", "summary": "This article focuses on the enterprise value to revenue forward metric for ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). It appears to be a financial data point from TradingView, indicating a specific valuation ratio for the company. The content itself seems to be a page header and n", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T20:17:05", "published_display": "09 Jul 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ANI Pharmaceuticals, Inc. \u2013 NASDAQ:ANIP", "summary": "This article provides financial information for ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) focusing on its price to sales forward metric. It displays market data and general financial overview for the company. The content appears to be a snapshot from a financial data platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T01:40:12", "published_display": "08 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Stronger Free Cash Flow Signalling a Shift in ANI Pharmaceuticals' Capital Efficiency Story (ANIP)?", "summary": "ANI Pharmaceuticals (ANIP) has demonstrated strong operational progress with 33.6% annual revenue growth and higher free cash flow margins, indicating improved efficiency. The company's recent raised 2026 revenue guidance and share repurchase authorization reflect management's co", "url": "https://www.sahmcapital.com/news/content/is-stronger-free-cash-flow-signalling-a-shift-in-ani-pharmaceuticals-capital-efficiency-story-anip-2026-07-07", "source_name": "Sahm", "published_at": "2026-07-07T23:41:19", "published_display": "07 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANIP (ANIP) insider sales reported: Walsh sold 13,973 shares in May 2026", "summary": "A Form 144 filing for ANI Pharmaceuticals (ANIP) reports that Patrick Walsh sold 13,973 shares in two transactions in May 2026, totaling over $1.1 million. The filing also indicates 4,336 restricted shares dated May 22, 2026, described as \"Securities To Be Sold\" from the issuer. ", "url": "https://www.stocktitan.net/sec-filings/ANIP/144-ani-pharmaceuticals-inc-sec-filing-a4182e093d72.html", "source_name": "Stock Titan", "published_at": "2026-07-07T19:39:22", "published_display": "07 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ani Pharmaceuticals SVP & CFO Stephen Carey sells $284k in stock", "summary": "Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals Inc., recently sold $284,918 worth of common stock after exercising stock options. This transaction occurred on July 2, 2026, under a pre-arranged trading plan. The company has shown strong financial performance, including a 31% ", "url": "https://www.investing.com/news/insider-trading-news/ani-pharmaceuticals-svp--cfo-stephen-carey-sells-284k-in-stock-93CH-4778182", "source_name": "Investing.com", "published_at": "2026-07-07T11:40:12", "published_display": "07 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 ANI Pharmaceuticals Inc For: 6 July By Investing.com", "summary": "This article reports on a Form 4 filing for ANI Pharmaceuticals Inc. (ANIP) for insider transactions that occurred on July 6th. The content is brief, primarily serving as an announcement for the filing, with no further details provided within the article itself. It includes stock", "url": "https://ca.investing.com/news/stock-market-news/form-4-ani-pharmaceuticals-inc-for-6-july-93CH-4722096", "source_name": "Investing.com Canada", "published_at": "2026-07-07T02:10:19", "published_display": "07 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) CFO sells 3,313 shares after option exercise", "summary": "Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals (ANIP), exercised stock options for 3,313 shares and subsequently sold all 3,313 shares at $86 each on July 2, 2026. This transaction was pre-arranged under a Rule 10b5-1 trading plan adopted on March 6, 2026. After the sale, Car", "url": "https://www.stocktitan.net/sec-filings/ANIP/form-4-ani-pharmaceuticals-inc-insider-trading-activity-d4acbd8fcc7f.html", "source_name": "Stock Titan", "published_at": "2026-07-07T02:10:19", "published_display": "07 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of ANI Pharmaceuticals, Inc. \u2013 NASDAQ:ANIP", "summary": "This page from TradingView provides financial information for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), specifically focusing on its forward price-to-earnings ratio. The content indicates that market data is provided by ICE Data Services and reference data by FactSet, with SEC fil", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T23:10:19", "published_display": "06 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ANI Pharmaceuticals, Inc. \u2013 NASDAQ:ANIP", "summary": "This article provides access to the \"Price to book forward\" financial data for ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) on TradingView. It highlights that the market was closed with no trades at the time of viewing. The page is part of TradingView's comprehensive financial data a", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T00:40:52", "published_display": "06 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals set to report earnings amid estimate cuts", "summary": "ANI Pharmaceuticals is scheduled to release its first-quarter earnings, with analysts expecting a sequential decline in EPS and revenue despite a year-over-year increase in revenue. Despite recent estimate cuts and a stock price below its 52-week high, analysts remain largely bul", "url": "https://www.investing.com/news/earnings/ani-pharmaceuticals-set-to-report-earnings-amid-estimate-cuts-93CH-4669381", "source_name": "Investing.com", "published_at": "2026-07-05T11:10:20", "published_display": "05 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of ANI Pharmaceuticals, Inc. \u2013 NASDAQ:ANIP", "summary": "This article provides financial data for ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed at the time of publication, and there were no trades. The content is primarily a data point ", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T10:10:28", "published_display": "04 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Stephen Carey Sells Shares of ANI Pharmaceuticals Inc (ANIP)", "summary": "Stephen Carey, Senior Vice President & Chief Financial Officer of ANI Pharmaceuticals Inc (ANIP), sold 2,850 shares on June 29, 2026, reducing his holdings to 177,543 shares. Over the past year, Carey has sold 63,474 shares, contributing to a total of 50 insider sells and no insi", "url": "https://www.gurufocus.com/news/8939593/insider-sell-stephen-carey-sells-shares-of-ani-pharmaceuticals-inc-anip", "source_name": "GuruFocus", "published_at": "2026-07-01T08:39:58", "published_display": "01 Jul 2026 08:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) CFO Stephen Carey sells 2,850 shares under Rule 10b5-1 plan", "summary": "ANI Pharmaceuticals' SVP & CFO, Stephen P. Carey, sold 2,850 shares of common stock at a weighted average price of $84.12 per share, totaling approximately $240,000. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026. Following t", "url": "https://www.stocktitan.net/sec-filings/ANIP/form-4-ani-pharmaceuticals-inc-insider-trading-activity-fc000f9a3ac9.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:15:16", "published_display": "30 Jun 2026 20:15", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ANIP)", "summary": "This article provides an overview of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) stock, including its current price, performance, and analyst forecasts. It also details financial actuals and estimates, such as earnings, revenue, net income, and market capitalization, along with freq", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T06:30:09", "published_display": "27 Jun 2026 06:30", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple (NASDAQ:ANIP)", "summary": "ANI Pharmaceuticals is presented as a speculative buy due to its transformational growth from Cortrophin Gel, a rare disease treatment. Management projects Cortrophin revenue to reach $540M-$575M by 2026, shifting the company's focus and potentially leading to a re-rating of its ", "url": "https://seekingalpha.com/article/4918037-ani-pharmaceuticals-rare-disease-growth-at-a-generics-multiple", "source_name": "Seeking Alpha", "published_at": "2026-06-26T14:39:12", "published_display": "26 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/buy-ani-pharmaceuticals-9-8x-172600284.html", "source_name": "Zacks", "published_at": "2026-06-10T17:26:00+00:00", "published_display": "10 Jun 2026 17:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Outperformers: ANI Pharmaceuticals (NASDAQ:ANIP) And The Rest Of The Pharmaceuticals Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQTnRnX1FWOEVnbUtrTDJxRV9yZEVIVWowQ1ZDbENGUnByN1M1SVdRd0VtRnJmVnBtaWxIN2lneGc1NHRBY2FOZjR5dE5HTnZ6ek1tMFF2ZmU4X3FjNVh6SXlVQ2pzOEFVQ3BtZ0dUY1FlZXRrY3JXVWN5b0xuR3RCcjRmdFNaRzZXbS0yOEVJc2RLekoyVk9YTDFLc05OUnBxaG1RbWZXRHhrRUM4dzdibHZmU0w?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Profitable Stocks: MYR Group & ANI Pharmaceuticals to Watch, B&G Foods to Sell - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQZWtMX2lraGZiR0pFOFlkSl9FTkFfdmpDMHJfNTJtSUx1Mlo0Z21JODhNd3VvV3ViMEh1NER0RmhnbDJsSjJTNFV1UG04c0FuYl94ajNPZHBoRGhMMjVBOVhKLTc2OGFVTmZYeTgtUGxsQ0xMTXJvRVVvN1VIUnhERC1NOTM?oc=5", "source_name": "IndexBox", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPVVZuZHhidVJram92TXMtZGw1Z2h1cXF0cFl4V1N2Q25EWWtGWGJLQlF4WWJOaXJQcndvRllxVjk5SUJRTlZEb19lU19xQ21oMUZZRnRvMHVjamZXUEdwUFkwamw4V1htZVFYTl94Z0VFbVJWTnFDaV95NDJ3bG5vblB2c2NQNUtkSzF1ODJ5dnNSOWhKTkkwLWRwNWZlS0QwTE41N2x0TVVIQmJYMFk0OXlWNnJpakFiTmk4T2ZJZTR0eUR5SzBsVHR3?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) Profit Swing And One Off Gain Test Bullish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) shares jump after earnings beat and higher outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOdDV0clZyaW84MlRqRVp4LTk2N3psMEdOaEczYm1oeXlqQmtQa2hsZWpIa3dDckJFbHNpTUVDTGFOWVZYTEhvVDY0b25GZGdIYi1COWlUTGhuS2tSYkk4dHBwN182eXpfTmFhcmVqVm5rNy1sTW96cjlpWHRMNnNFbHlVQnJZdWdwM3NDWENlbV9FZS03OG9pQWF6bGE5MFc3WWVaVFZYbTc?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPLTBLN0xYRDZKZVdXTmY5VEo1TWZudEk4dXJXME40ZE9aQzZyQW4yZElleG9DZ2tCYlprclY2Y0EtQW5KY0gtZDVVLWFSNjZ3SnhkUmlhTlEyOXhUWkFmUUN1dWQxYjg4VEp3emNaMGV1WHRmY2hkT3lEN0FlcUZpSEtHRWpoOWYwOTc2TFhhME1sTGtnUlNIYl80OXRMQzcxMEhsSTAtc1VIbnh3NWswZjhkQUFXQ05kTW1Obms0NEI0cFIySGxONklhVlFVVU5abFRVTWlRZzlfSzBqUXVDcUp5XzdCbl9xVXNLenB1TThVU3lzMHVNTTFHZXo4Ui1H?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) Q1 Earnings: What To Expect", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQOE9JZ3lyQXdaX2xDbVZ1VFJ6RmtaZFY0QzlMQUczMmEtb3k3ckdvQkR6QzVTTGpqZW4zQ2NCcEpxSzZ1a0pZbTNvU0JtbXFXVVBYNXlKaVBLUE5sWVN2MjgyQzFvTzB3TUNIQ29YdHRONG10aGExMDZvZlNQUFNuY2ZyODNvT2lxTGdQTmtscnhxYTdQOFlmZEZTSTkwU3lJaGI1UjNUSmJmZjd3NUUw?oc=5", "source_name": "StockStory", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQQ1dqY0Q4Mm9wQVNvZzlsb2kyZDVrblAyS0pOZFNzZnBORzBsU0xUOW51ZEZ3YVcwUWl6c0xnMElkUjdleE5wcE9WaW9FTlY4TzZaVVpHQmNDaGFnMVlSd0hTQV84STlvd2pkYUEtQkpPZS1QdEVkZmdzVjFCT2ozRTVjVlliTV94cmFud3M5YTVGMUYtVmJOT1NiV2pvQmFFOWQ5YzE1V2g?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ANI Pharmaceuticals (ANIP) Pricing Reflect Its Strong Multi Year Share Price Performance?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals News Highlights Undervalued Shares And New Specialty Generics", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxOYjNCTEw1V2kwZHl4NnhLWHRGbXY5SGd3VGd1N1RENlpNUXI4bDlncjlsNURudXFTeEVER1pyYi1zNzFFTDhSQ0tVeXVpR3loeHNoVHZIWTc1cVhQSEMxSmpRaUVTS2oxWGFVMUw1N0RLVC05NzF6RjJkelBKX2VFUkR1SHpQUU54TFdUSkcxYjZVQUFQY0dKVHpQdWoxZExTd2JDSC1CM3lMVFdnQ2JFVHhSY2JkV19nRXFyMVZUeGhMOHZvSUtXV1ZyWHBKM0pQQm5ESUV3X3Bzdm4zUWJJMGVTbVo1M3V40gHuAUFVX3lxTE44a0Q2RG1YWTYwTXdrTHF4MWxzc2wyM3YwRmZMSkhYY1MzeWdBZTREWVpLY201RVhLdk92RW1tdVcyR3p5bzBHVkJYdFlwdzRPWkJPTVRYckRkc2JRSGFOYXFRamVpRXFrbGhKMEJxSTBQWFQxYjRITUJlSkZiZHhMLTB0MkRua3lQRzRDV2N4R2NxWXNPX2dXemxoRUc2eURtb1hUSzU0U0xCWGtTZWQxQ3JaaC10UFI3dVZOdDhRVE5FMnhrSVRualJsa3hVR3JveUZ5TlQ4TzFZYlZXb1RCOEdqSkNCWC1uUjk3RUE?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQbDQ2aEYxNlo3MHlwN3hfZTZ4eFRNem9FRGd5b3ZOOWhYdmpNZmJ2azdTdURVQnh1dzNENDVQa3JRbktvNlVuc04xbmx1eXZnQk5ncW5WTHVOUjFLNDc4aFpyMU5DMC1OSE1mSlVOSERVNjJidUdvM1FPelRLQjRDdnFnNTJBU2FaN1VSVTdGNHRGZWhpME1XN2FiUU0xOFVxTFA0YUFxOC1yRnRkUXFiV3E2eUFiY1R5SGc?oc=5", "source_name": "TradingView", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPZnp4Z3FwZ0hHQkpYOVEwWVdGRWR5cll0NDd5TlVoX1Bhb0FCaFlGS01qSlVLbVRYUE0xZUg4bjd0dzBuTmZSWWpBQWJkY2kxbEJHT1lxVEw3ZnpKdjFXZGd4cGw5cl9mWE1kZVFfYU1NNGxJMWZoRUE5ZzdfeHM1ck9PVElDNWM3anRr?oc=5", "source_name": "Market source", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter", "summary": "ANI Pharmaceuticals (ANIP) announced its intent to appeal rulings in the CG Oncology matter to the Delaware Supreme Court after a trial court denied its motions for a new trial and judgment. The company aims to recover the value of assets sold to CG Oncology in 2010, specifically", "url": "https://sg.finance.yahoo.com/news/ani-pharmaceuticals-announces-intent-appeal-203400188.html", "source_name": "Market source", "published_at": "2026-07-17T02:10:03", "published_display": "17 Jul 2026 02:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals plans appeal after trial court ruling By Investing.com", "summary": "ANI Pharmaceuticals announced its intent to appeal a Delaware trial court's denial of its post-trial motions in a dispute with CG Oncology. The company is seeking to recover the value of assets sold in 2010 and a 5% running royalty on future sales of cretostimogene grenadenorepve", "url": "https://ca.investing.com/news/stock-market-news/ani-pharmaceuticals-plans-appeal-after-trial-court-ruling-93CH-4738454", "source_name": "Investing.com Canada", "published_at": "2026-07-17T02:05:03", "published_display": "17 Jul 2026 02:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals Plans to Appeal Trial Court Rulings in CG Oncology Case", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ani-pharmaceuticals-plans-appeal-trial-211922359.html", "source_name": "MT Newswires", "published_at": "2026-07-16T21:19:22+00:00", "published_display": "16 Jul 2026 21:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPWDBfMjVQZWJ4bFFwbjUycnpmYUFsRm1hb1BvYi0xaXNTZ0MtYzYyUGVKQ21Mb2dselNjdnM1Q3NXSXR5VUdsWm91OUZLNnVnQkpsUFF0ZlNwWGVGc0FVSEVhSzAyWnRmVGYtX1hUUW9CZGVOaENBcVhhcERRN1hSZQ?oc=5", "source_name": "AOL.com", "published_at": "2026-07-16T19:39:25+00:00", "published_display": "16 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Frontier tech research, news & data", "summary": "This article analyzes the growth of ANI Pharmaceuticals Inc. (ANIP), focusing on its revenue, net income, and EPS growth rates year-over-year. It provides a detailed breakdown of these financial metrics on both an annual and quarterly (trailing-twelve-month) basis, highlighting s", "url": "https://mlq.ai/companies/ani-pharmaceuticals-inc/growth/", "source_name": "MLQ.ai", "published_at": "2026-07-15T04:45:33", "published_display": "15 Jul 2026 04:45", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Meredith Cook Sells 500 Shares of ANI Pharmaceuticals Inc (ANIP)", "summary": "Meredith Cook, Senior Vice President at ANI Pharmaceuticals Inc (ANIP), sold 500 shares of the company on July 13, 2026. This transaction continues a trend of insider selling over the past year, with no insider buys recorded against 52 insider sells. The stock is currently priced", "url": "https://www.gurufocus.com/news/8958706/insider-sell-meredith-cook-sells-500-shares-of-ani-pharmaceuticals-inc-anip", "source_name": "GuruFocus", "published_at": "2026-07-14T22:41:05", "published_display": "14 Jul 2026 22:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) counsel sells 500 shares under 10b5-1 plan", "summary": "ANI Pharmaceuticals' Senior Vice President, General Counsel, and Secretary, Meredith Cook, sold 500 shares of common stock at $81.84 per share on July 13, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established in September 2025. Following the sale, Cook", "url": "https://www.stocktitan.net/sec-filings/ANIP/form-4-ani-pharmaceuticals-inc-insider-trading-activity-df1390ac52a4.html", "source_name": "Stock Titan", "published_at": "2026-07-14T19:41:05", "published_display": "14 Jul 2026 19:41", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis", "summary": "ANI Pharmaceuticals announced positive six-month topline data from its Phase 4 SYNCHRONICITY clinical trial evaluating Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis (NIU-PS). The trial met both co-primary endpoints, showing statistica", "url": "https://www.sahmcapital.com/news/content/ani-pharmaceuticals-announces-positive-six-month-topline-data-from-the-phase-4-open-label-single-arm-synchronicity-trial-evaluating-fluocinolone-acetonide-intravitreal-implant-in-patients-with-chronic-non-infectious-uveitis-2026-07-13", "source_name": "Sahm", "published_at": "2026-07-14T02:10:03", "published_display": "14 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant", "summary": "ANI Pharmaceuticals Inc (NASDAQ:ANIP) announced positive topline results from its Phase 4 SYNCHRONICITY trial for a fluocinolone acetonide intravitreal implant used to treat chronic non-infectious uveitis. The study successfully met both primary endpoints, showing improved vision", "url": "https://www.proactiveinvestors.com.au/companies/news/1095359/ani-pharmaceuticals-reports-phase-4-data-for-uveitis-eye-implant-1095359.html", "source_name": "Proactive financial news", "published_at": "2026-07-13T13:41:19", "published_display": "13 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eye implant trial from ANI Pharmaceuticals improves vision and retinal thickness at 6 months", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNRVAwTllqdlQ1ZGQxX1lfYnZFZUNlOXpMLW92eUtGSFRhODNPNV9pNWZLY2dSX1R4UjY2bFJZZlVvZEVoTjRCbm5BLUV2U08wMTYwdmJKbnY3MG1FYW1KMEU0UktYaWo4dTJhR3V5b3RHUE85VWhjTlJXX3IweWJmSC16UFVpZVVlQ1FSd09CejdwdldBM3JZZVJBTF9FejZtUG5qWEdyVGFFWm4xWWJqd0I2aC15VzRxbkIzVjJn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:50:00+00:00", "published_display": "13 Jul 2026 10:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals reports positive phase 4 trial results", "summary": "ANI Pharmaceuticals (NASDAQ: ANIP) announced positive results from its Phase 4 SYNCHRONICITY clinical trial for fluocinolone acetonide intravitreal implant, which met both co-primary endpoints for treating chronic non-infectious uveitis. The trial demonstrated significant improve", "url": "https://www.investing.com/news/company-news/ani-pharmaceuticals-reports-positive-phase-4-trial-results-93CH-4787990", "source_name": "Investing.com", "published_at": "2026-07-13T11:10:25", "published_display": "13 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals reports positive uveitis trial results", "summary": "ANI Pharmaceuticals (NASDAQ:ANIP) announced positive six-month results from its Phase 4 SYNCHRONICITY trial for a fluocinolone acetonide intravitreal implant used to treat chronic non-infectious uveitis. The trial met both primary endpoints, demonstrating significant improvements", "url": "https://grafa.com/en/news/united-states/ani-pharmaceuticals-synchronicity-uveitis-trial-results", "source_name": "grafa.com", "published_at": "2026-07-13T11:06:00", "published_display": "13 Jul 2026 11:06", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of ANI Pharmaceuticals, Inc. \u2013 BX:BSFA", "summary": "This article focuses on the enterprise value to EBIT forward ratio for ANI Pharmaceuticals, Inc. (BX:BSFA). It appears to be a financial data point from TradingView, indicating a specific financial metric for the company. The content itself seems to be a page snippet from a finan", "url": "https://www.tradingview.com/symbols/BX-BSFA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T01:10:25", "published_display": "13 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) Recalls HydrOXYzine Solution, Is The Pullback A Valuation Opportunity?", "summary": "ANI Pharmaceuticals has initiated a Class III recall of its hydrOXYzine Hydrochloride Oral Solution due to a foreign substance, causing a short-term dip in its stock price. Despite this, the company has shown strong long-term shareholder returns, and a widely followed valuation n", "url": "https://www.sahmcapital.com/news/content/ani-pharmaceuticals-anip-recalls-hydroxyzine-solution-is-the-pullback-a-valuation-opportunity-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T13:40:04", "published_display": "11 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge", "summary": "Stephen Carey, CFO of ANI Pharmaceuticals, sold 2,850 shares of common stock worth $239,742 as part of a pre-scheduled Rule 10b5-1 plan. This sale represented a modest 1.6% reduction of his direct holdings and is not considered a signal of a negative outlook on the company. The c", "url": "https://finance.yahoo.com/markets/stocks/articles/ani-pharmaceuticals-cfo-sells-240-215646356.html", "source_name": "Market source", "published_at": "2026-07-09T22:17:05", "published_display": "09 Jul 2026 22:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of ANI Pharmaceuticals, Inc. \u2013 NASDAQ:ANIP", "summary": "This article focuses on the enterprise value to revenue forward metric for ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). It appears to be a financial data point from TradingView, indicating a specific valuation ratio for the company. The content itself seems to be a page header and n", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T20:17:05", "published_display": "09 Jul 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ANI Pharmaceuticals, Inc. \u2013 NASDAQ:ANIP", "summary": "This article provides financial information for ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) focusing on its price to sales forward metric. It displays market data and general financial overview for the company. The content appears to be a snapshot from a financial data platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T01:40:12", "published_display": "08 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Stronger Free Cash Flow Signalling a Shift in ANI Pharmaceuticals' Capital Efficiency Story (ANIP)?", "summary": "ANI Pharmaceuticals (ANIP) has demonstrated strong operational progress with 33.6% annual revenue growth and higher free cash flow margins, indicating improved efficiency. The company's recent raised 2026 revenue guidance and share repurchase authorization reflect management's co", "url": "https://www.sahmcapital.com/news/content/is-stronger-free-cash-flow-signalling-a-shift-in-ani-pharmaceuticals-capital-efficiency-story-anip-2026-07-07", "source_name": "Sahm", "published_at": "2026-07-07T23:41:19", "published_display": "07 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANIP (ANIP) insider sales reported: Walsh sold 13,973 shares in May 2026", "summary": "A Form 144 filing for ANI Pharmaceuticals (ANIP) reports that Patrick Walsh sold 13,973 shares in two transactions in May 2026, totaling over $1.1 million. The filing also indicates 4,336 restricted shares dated May 22, 2026, described as \"Securities To Be Sold\" from the issuer. ", "url": "https://www.stocktitan.net/sec-filings/ANIP/144-ani-pharmaceuticals-inc-sec-filing-a4182e093d72.html", "source_name": "Stock Titan", "published_at": "2026-07-07T19:39:22", "published_display": "07 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ani Pharmaceuticals SVP & CFO Stephen Carey sells $284k in stock", "summary": "Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals Inc., recently sold $284,918 worth of common stock after exercising stock options. This transaction occurred on July 2, 2026, under a pre-arranged trading plan. The company has shown strong financial performance, including a 31% ", "url": "https://www.investing.com/news/insider-trading-news/ani-pharmaceuticals-svp--cfo-stephen-carey-sells-284k-in-stock-93CH-4778182", "source_name": "Investing.com", "published_at": "2026-07-07T11:40:12", "published_display": "07 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 ANI Pharmaceuticals Inc For: 6 July By Investing.com", "summary": "This article reports on a Form 4 filing for ANI Pharmaceuticals Inc. (ANIP) for insider transactions that occurred on July 6th. The content is brief, primarily serving as an announcement for the filing, with no further details provided within the article itself. It includes stock", "url": "https://ca.investing.com/news/stock-market-news/form-4-ani-pharmaceuticals-inc-for-6-july-93CH-4722096", "source_name": "Investing.com Canada", "published_at": "2026-07-07T02:10:19", "published_display": "07 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) CFO sells 3,313 shares after option exercise", "summary": "Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals (ANIP), exercised stock options for 3,313 shares and subsequently sold all 3,313 shares at $86 each on July 2, 2026. This transaction was pre-arranged under a Rule 10b5-1 trading plan adopted on March 6, 2026. After the sale, Car", "url": "https://www.stocktitan.net/sec-filings/ANIP/form-4-ani-pharmaceuticals-inc-insider-trading-activity-d4acbd8fcc7f.html", "source_name": "Stock Titan", "published_at": "2026-07-07T02:10:19", "published_display": "07 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of ANI Pharmaceuticals, Inc. \u2013 NASDAQ:ANIP", "summary": "This page from TradingView provides financial information for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), specifically focusing on its forward price-to-earnings ratio. The content indicates that market data is provided by ICE Data Services and reference data by FactSet, with SEC fil", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T23:10:19", "published_display": "06 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ANI Pharmaceuticals, Inc. \u2013 NASDAQ:ANIP", "summary": "This article provides access to the \"Price to book forward\" financial data for ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) on TradingView. It highlights that the market was closed with no trades at the time of viewing. The page is part of TradingView's comprehensive financial data a", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T00:40:52", "published_display": "06 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals set to report earnings amid estimate cuts", "summary": "ANI Pharmaceuticals is scheduled to release its first-quarter earnings, with analysts expecting a sequential decline in EPS and revenue despite a year-over-year increase in revenue. Despite recent estimate cuts and a stock price below its 52-week high, analysts remain largely bul", "url": "https://www.investing.com/news/earnings/ani-pharmaceuticals-set-to-report-earnings-amid-estimate-cuts-93CH-4669381", "source_name": "Investing.com", "published_at": "2026-07-05T11:10:20", "published_display": "05 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of ANI Pharmaceuticals, Inc. \u2013 NASDAQ:ANIP", "summary": "This article provides financial data for ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed at the time of publication, and there were no trades. The content is primarily a data point ", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T10:10:28", "published_display": "04 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Stephen Carey Sells Shares of ANI Pharmaceuticals Inc (ANIP)", "summary": "Stephen Carey, Senior Vice President & Chief Financial Officer of ANI Pharmaceuticals Inc (ANIP), sold 2,850 shares on June 29, 2026, reducing his holdings to 177,543 shares. Over the past year, Carey has sold 63,474 shares, contributing to a total of 50 insider sells and no insi", "url": "https://www.gurufocus.com/news/8939593/insider-sell-stephen-carey-sells-shares-of-ani-pharmaceuticals-inc-anip", "source_name": "GuruFocus", "published_at": "2026-07-01T08:39:58", "published_display": "01 Jul 2026 08:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) CFO Stephen Carey sells 2,850 shares under Rule 10b5-1 plan", "summary": "ANI Pharmaceuticals' SVP & CFO, Stephen P. Carey, sold 2,850 shares of common stock at a weighted average price of $84.12 per share, totaling approximately $240,000. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026. Following t", "url": "https://www.stocktitan.net/sec-filings/ANIP/form-4-ani-pharmaceuticals-inc-insider-trading-activity-fc000f9a3ac9.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:15:16", "published_display": "30 Jun 2026 20:15", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ANIP)", "summary": "This article provides an overview of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) stock, including its current price, performance, and analyst forecasts. It also details financial actuals and estimates, such as earnings, revenue, net income, and market capitalization, along with freq", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T06:30:09", "published_display": "27 Jun 2026 06:30", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple (NASDAQ:ANIP)", "summary": "ANI Pharmaceuticals is presented as a speculative buy due to its transformational growth from Cortrophin Gel, a rare disease treatment. Management projects Cortrophin revenue to reach $540M-$575M by 2026, shifting the company's focus and potentially leading to a re-rating of its ", "url": "https://seekingalpha.com/article/4918037-ani-pharmaceuticals-rare-disease-growth-at-a-generics-multiple", "source_name": "Seeking Alpha", "published_at": "2026-06-26T14:39:12", "published_display": "26 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/buy-ani-pharmaceuticals-9-8x-172600284.html", "source_name": "Zacks", "published_at": "2026-06-10T17:26:00+00:00", "published_display": "10 Jun 2026 17:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Outperformers: ANI Pharmaceuticals (NASDAQ:ANIP) And The Rest Of The Pharmaceuticals Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQTnRnX1FWOEVnbUtrTDJxRV9yZEVIVWowQ1ZDbENGUnByN1M1SVdRd0VtRnJmVnBtaWxIN2lneGc1NHRBY2FOZjR5dE5HTnZ6ek1tMFF2ZmU4X3FjNVh6SXlVQ2pzOEFVQ3BtZ0dUY1FlZXRrY3JXVWN5b0xuR3RCcjRmdFNaRzZXbS0yOEVJc2RLekoyVk9YTDFLc05OUnBxaG1RbWZXRHhrRUM4dzdibHZmU0w?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Profitable Stocks: MYR Group & ANI Pharmaceuticals to Watch, B&G Foods to Sell - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQZWtMX2lraGZiR0pFOFlkSl9FTkFfdmpDMHJfNTJtSUx1Mlo0Z21JODhNd3VvV3ViMEh1NER0RmhnbDJsSjJTNFV1UG04c0FuYl94ajNPZHBoRGhMMjVBOVhKLTc2OGFVTmZYeTgtUGxsQ0xMTXJvRVVvN1VIUnhERC1NOTM?oc=5", "source_name": "IndexBox", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPVVZuZHhidVJram92TXMtZGw1Z2h1cXF0cFl4V1N2Q25EWWtGWGJLQlF4WWJOaXJQcndvRllxVjk5SUJRTlZEb19lU19xQ21oMUZZRnRvMHVjamZXUEdwUFkwamw4V1htZVFYTl94Z0VFbVJWTnFDaV95NDJ3bG5vblB2c2NQNUtkSzF1ODJ5dnNSOWhKTkkwLWRwNWZlS0QwTE41N2x0TVVIQmJYMFk0OXlWNnJpakFiTmk4T2ZJZTR0eUR5SzBsVHR3?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) Profit Swing And One Off Gain Test Bullish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) shares jump after earnings beat and higher outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOdDV0clZyaW84MlRqRVp4LTk2N3psMEdOaEczYm1oeXlqQmtQa2hsZWpIa3dDckJFbHNpTUVDTGFOWVZYTEhvVDY0b25GZGdIYi1COWlUTGhuS2tSYkk4dHBwN182eXpfTmFhcmVqVm5rNy1sTW96cjlpWHRMNnNFbHlVQnJZdWdwM3NDWENlbV9FZS03OG9pQWF6bGE5MFc3WWVaVFZYbTc?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPLTBLN0xYRDZKZVdXTmY5VEo1TWZudEk4dXJXME40ZE9aQzZyQW4yZElleG9DZ2tCYlprclY2Y0EtQW5KY0gtZDVVLWFSNjZ3SnhkUmlhTlEyOXhUWkFmUUN1dWQxYjg4VEp3emNaMGV1WHRmY2hkT3lEN0FlcUZpSEtHRWpoOWYwOTc2TFhhME1sTGtnUlNIYl80OXRMQzcxMEhsSTAtc1VIbnh3NWswZjhkQUFXQ05kTW1Obms0NEI0cFIySGxONklhVlFVVU5abFRVTWlRZzlfSzBqUXVDcUp5XzdCbl9xVXNLenB1TThVU3lzMHVNTTFHZXo4Ui1H?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) Q1 Earnings: What To Expect", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQOE9JZ3lyQXdaX2xDbVZ1VFJ6RmtaZFY0QzlMQUczMmEtb3k3ckdvQkR6QzVTTGpqZW4zQ2NCcEpxSzZ1a0pZbTNvU0JtbXFXVVBYNXlKaVBLUE5sWVN2MjgyQzFvTzB3TUNIQ29YdHRONG10aGExMDZvZlNQUFNuY2ZyODNvT2lxTGdQTmtscnhxYTdQOFlmZEZTSTkwU3lJaGI1UjNUSmJmZjd3NUUw?oc=5", "source_name": "StockStory", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQQ1dqY0Q4Mm9wQVNvZzlsb2kyZDVrblAyS0pOZFNzZnBORzBsU0xUOW51ZEZ3YVcwUWl6c0xnMElkUjdleE5wcE9WaW9FTlY4TzZaVVpHQmNDaGFnMVlSd0hTQV84STlvd2pkYUEtQkpPZS1QdEVkZmdzVjFCT2ozRTVjVlliTV94cmFud3M5YTVGMUYtVmJOT1NiV2pvQmFFOWQ5YzE1V2g?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ANI Pharmaceuticals (ANIP) Pricing Reflect Its Strong Multi Year Share Price Performance?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals News Highlights Undervalued Shares And New Specialty Generics", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQbDQ2aEYxNlo3MHlwN3hfZTZ4eFRNem9FRGd5b3ZOOWhYdmpNZmJ2azdTdURVQnh1dzNENDVQa3JRbktvNlVuc04xbmx1eXZnQk5ncW5WTHVOUjFLNDc4aFpyMU5DMC1OSE1mSlVOSERVNjJidUdvM1FPelRLQjRDdnFnNTJBU2FaN1VSVTdGNHRGZWhpME1XN2FiUU0xOFVxTFA0YUFxOC1yRnRkUXFiV3E2eUFiY1R5SGc?oc=5", "source_name": "TradingView", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPZnp4Z3FwZ0hHQkpYOVEwWVdGRWR5cll0NDd5TlVoX1Bhb0FCaFlGS01qSlVLbVRYUE0xZUg4bjd0dzBuTmZSWWpBQWJkY2kxbEJHT1lxVEw3ZnpKdjFXZGd4cGw5cl9mWE1kZVFfYU1NNGxJMWZoRUE5ZzdfeHM1ck9PVElDNWM3anRr?oc=5", "source_name": "Market source", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 89, "total_relevant": 44, "sentiment_summary": {"positive": 12, "negative": 7, "neutral": 25, "score": 55, "total": 44, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 13.75, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 9.5, "count": 16}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 82.07, "latest_week": "2026-07-10", "one_week_move": -4.6, "four_week_move": 0.5, "twelve_week_move": 1.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.924261, "market_dynamics_buy_signal": false, "relative_strength": -14.622318, "fair_value_gap": 21.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 50.0386, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.6% over one week, +0.5% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 8}, {"label": "Market source", "count": 6}, {"label": "Stock Titan", "count": 5}, {"label": "Sahm", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com Canada", "count": 2}, {"label": "GuruFocus", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 16}, {"label": "Regulatory and legal", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-4.6% over one week, +0.5% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter"}], "updated_at": "2026-07-17T05:31:12.651887+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}